Lisinopril combined with atenolol in the treatment of hypertension. Swedish Lisinopril Study Group.
This is a double-blind, randomized parallel-group multicenter study comprising 340 hypertensive patients. All were treated with 50 mg of atenolol once daily. If their recumbent diastolic blood pressure was greater than or equal to 95 and less than or equal to 115 mm Hg after a 4-week open run-in period, patients were randomized to receive additionally, 5, 10, or 20 mg of lisinopril once daily or placebo for a further 8-week period in a double-blind fashion. The additional effects on the trough (24-28 h after tablet intake) diastolic blood pressure of placebo and 5 mg of lisinopril were not statistically significant. Lisinopril at 10 and 20 mg reduced the recumbent diastolic blood pressure by 3.2 and 3.3 mm Hg, respectively, more than placebo (p = 0.010-0.011). The recumbent systolic blood pressure and heart rate did not change. The side effect profile of lisinopril was not different from that of placebo and adverse effects were few and mild.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004562:Electrocardiography; D004656:Enalapril / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017706:Lisinopril; D008297:Male; D008875:Middle Aged; D013548:Sweden
D000806:Angiotensin-Converting Enzyme Inhibitors; D001262:Atenolol; D004656:Enalapril; D017706:Lisinopril